Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EcN::ttr
- Development stage
- Preclinical
- Lead developer
- Melius MicroBiomics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
EcN::ttr is a genetically engineered microbiome medicine (GEMM) developed by Melius MicroBiomics for veterinary applications in pork production. The product consists of the probiotic bacterium *E. coli* Nissle 1917 (EcN) modified with tetrathionate respiration (ttr) capability using the company's BioPersist™ technology platform. This engineering allows the probiotic to utilize tetrathionate—a metabolite produced by the host during intestinal inflammation—as an alternative electron acceptor for anaerobic respiration. This provides the engineered strain with a significant competitive growth advantage in the inflamed gut environment where native probiotics often fail. Administered as an oral feed additive, EcN::ttr is designed to mitigate post-weaning stress in pigs by reducing diarrhea, infection, and mortality, while simultaneously improving feed efficiency and average daily weight gain by modulating the porcine gut microbiome and reducing intestinal permeability (leaky gut).
- Other names
- EcN::ttr (Pig)engineered E. coli Nissle 1917
02
Targets
S4O6 (Tetrathionate)
Beyond the preview
Go deeper on EcN::ttr.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EcN::ttr.